BRIEF-Sino Biopharmaceutical Announces Exclusive License And Cooperation Deal With YZY Biopharma

Reuters10-08

Oct 8 (Reuters) - Sino Biopharmaceutical Ltd :

* SIGNING OF AN EXCLUSIVE LICENSE AND COOPERATION AGREEMENT WITH YZY BIOPHARMA

* UNIT WILL PAY APPROXIMATELY RMB315 MILLION AS UPFRONT PAYMENT

* UNDER DEAL, UNIT WILL PAY SALES MILESTONE PAYMENTS OF UP TO RMB700 MILLION TO YZY BIOPHARMA

* UNIT OBTAINED LICENSE FOR DEVELOPMENT, COMMERCIALIZATION OF M701 DEVELOPED BY YZY BIOPHARMA IN MAINLAND CHINA

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473452644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473452644","market":"hk","top_or_hot":-1,"title":"BRIEF-Sino Biopharmaceutical Announces Exclusive License And Cooperation Deal With YZY Biopharma","media":"Reuters","content":"<html><body><p>Oct 8 (Reuters) - Sino Biopharmaceutical Ltd   :</p><p>   * SIGNING OF AN EXCLUSIVE LICENSE AND COOPERATION AGREEMENT WITH YZY BIOPHARMA</p><p>   * UNIT WILL PAY APPROXIMATELY RMB315 MILLION AS UPFRONT PAYMENT</p><p>   * UNDER DEAL, UNIT  WILL PAY SALES MILESTONE PAYMENTS OF UP TO RMB700 MILLION TO YZY BIOPHARMA</p><p>   * UNIT OBTAINED LICENSE FOR DEVELOPMENT, COMMERCIALIZATION OF M701 DEVELOPED BY YZY BIOPHARMA IN MAINLAND CHINA</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sino Biopharmaceutical Announces Exclusive License And Cooperation Deal With YZY Biopharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sino Biopharmaceutical Announces Exclusive License And Cooperation Deal With YZY Biopharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 09:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 8 (Reuters) - Sino Biopharmaceutical Ltd   :   * SIGNING OF AN EXCLUSIVE LICENSE AND COOPERATION AGREEMENT WITH YZY BIOPHARMA   * UNIT WILL PAY APPROXIMATELY RMB315 MILLION AS UPFRONT PAYMENT   * ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2473452644","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473452644","pubTimestamp":1728350183,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 8  - Sino Biopharmaceutical Ltd   :   * SIGNING OF AN EXCLUSIVE LICENSE AND COOPERATION AGREEMENT WITH YZY BIOPHARMA   * UNIT WILL PAY APPROXIMATELY RMB315 MILLION AS UPFRONT PAYMENT   * UNDER DEAL, UNIT  WILL PAY SALES MILESTONE PAYMENTS OF UP TO RMB700 MILLION TO YZY BIOPHARMA   * UNIT OBTAINED LICENSE FOR DEVELOPMENT, COMMERCIALIZATION OF M701 DEVELOPED BY YZY BIOPHARMA IN MAINLAND CHINA Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","01177":"中国生物制药","BK1589":"北水核心资产","BK1521":"挪威政府全球养老基金持仓"},"translate_title":"简介-中国生物制药宣布与YZY Biopharma达成独家许可及合作协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"Oct 8 (Reuters) - Sino Biopharmaceutical Ltd   :   * SIGNING OF AN EXCLUSIVE LICENSE AND COOPERATION AGREEMENT WITH YZY BIOPHARMA   * UNIT WILL PAY APPROXIMATELY RMB315 MILLION AS UPFRONT PAYMENT   * UNDER DEAL, UNIT  WILL PAY SALES MILESTONE PAYMENTS OF UP TO RMB700 MILLION TO YZY BIOPHARMA   * UNIT OBTAINED LICENSE FOR DEVELOPMENT, COMMERCIALIZATION OF M701 DEVELOPED BY YZY BIOPHARMA IN MAINLAND CHINA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473452644"}